Programmed cell death 1 expression is associated with inferior survival in patients with primary central nervous system lymphoma

Hyunsoo Cho, Se Hoon Kim, Soo Jeong Kim, Jong Hee Chang, Woo Ick Yang, Chang Ok Suh, Yu Ri Kim, Ji Eun Jang, June Won Cheong, Yoo Hong Min, Jin Seok Kim

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Programmed cell death 1 (PD-1) and its ligands PD-L1/PD-L2 have been shown to mediate immune evasion in various cancers, but their prognostic implications in patients with primary central nervous system lymphoma (PCNSL) are poorly understood. Therefore, we analyzed 76 PCNSL patients at initial diagnosis who were treated homogenously with high-dose methotrexate-based chemotherapy, and evaluated the prognostic roles of high immunohistochemical PD-1, PD-L1, and PD-L2 expression. The cut-off values for high PD-1 (≥ 70 cells/high power field [HPF]), PD-L1 (≥ 100 cells/HPF), and PD-L2 (≥ 100 cells/HPF) were determined by the area under the receiver operating characteristic curve. Expression of PD-1, PD-L1, and PD-L2 was high in 7.9%, 13.2%, and 42.1% patients, respectively. High PD-1, (P = 0.007) and Memorial Sloan Kettering Cancer Center (MSKCC) prognostic scoring (P = 0.019) were independently associated with inferior overall survival on multivariate analysis. High PD-1 also remained an independent prognostic factor for inferior progression-free survival (P = 0.028), as did MSKCC prognostic scoring (P = 0.041) on multivariate analysis. However, there were no differences in survival according to the expression levels of PD-L1/PD-L2 in PCNSL tumor microenvironment. Our results suggest that PD-1 may be considered a biomarker and potential therapeutic target in PCNSL.

Original languageEnglish
Pages (from-to)87317-87328
Number of pages12
JournalOncotarget
Volume8
Issue number50
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Lymphoma
Cell Death
Central Nervous System
Survival
Multivariate Analysis
Immune Evasion
Central Nervous System Neoplasms
Neoplasms
Tumor Microenvironment
Methotrexate
ROC Curve
Disease-Free Survival
Biomarkers
Ligands
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Cho, Hyunsoo ; Kim, Se Hoon ; Kim, Soo Jeong ; Chang, Jong Hee ; Yang, Woo Ick ; Suh, Chang Ok ; Kim, Yu Ri ; Jang, Ji Eun ; Cheong, June Won ; Min, Yoo Hong ; Kim, Jin Seok. / Programmed cell death 1 expression is associated with inferior survival in patients with primary central nervous system lymphoma. In: Oncotarget. 2017 ; Vol. 8, No. 50. pp. 87317-87328.
@article{7194a376e29d4ecdb048ef20b3d94cd6,
title = "Programmed cell death 1 expression is associated with inferior survival in patients with primary central nervous system lymphoma",
abstract = "Programmed cell death 1 (PD-1) and its ligands PD-L1/PD-L2 have been shown to mediate immune evasion in various cancers, but their prognostic implications in patients with primary central nervous system lymphoma (PCNSL) are poorly understood. Therefore, we analyzed 76 PCNSL patients at initial diagnosis who were treated homogenously with high-dose methotrexate-based chemotherapy, and evaluated the prognostic roles of high immunohistochemical PD-1, PD-L1, and PD-L2 expression. The cut-off values for high PD-1 (≥ 70 cells/high power field [HPF]), PD-L1 (≥ 100 cells/HPF), and PD-L2 (≥ 100 cells/HPF) were determined by the area under the receiver operating characteristic curve. Expression of PD-1, PD-L1, and PD-L2 was high in 7.9{\%}, 13.2{\%}, and 42.1{\%} patients, respectively. High PD-1, (P = 0.007) and Memorial Sloan Kettering Cancer Center (MSKCC) prognostic scoring (P = 0.019) were independently associated with inferior overall survival on multivariate analysis. High PD-1 also remained an independent prognostic factor for inferior progression-free survival (P = 0.028), as did MSKCC prognostic scoring (P = 0.041) on multivariate analysis. However, there were no differences in survival according to the expression levels of PD-L1/PD-L2 in PCNSL tumor microenvironment. Our results suggest that PD-1 may be considered a biomarker and potential therapeutic target in PCNSL.",
author = "Hyunsoo Cho and Kim, {Se Hoon} and Kim, {Soo Jeong} and Chang, {Jong Hee} and Yang, {Woo Ick} and Suh, {Chang Ok} and Kim, {Yu Ri} and Jang, {Ji Eun} and Cheong, {June Won} and Min, {Yoo Hong} and Kim, {Jin Seok}",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.20264",
language = "English",
volume = "8",
pages = "87317--87328",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "50",

}

Programmed cell death 1 expression is associated with inferior survival in patients with primary central nervous system lymphoma. / Cho, Hyunsoo; Kim, Se Hoon; Kim, Soo Jeong; Chang, Jong Hee; Yang, Woo Ick; Suh, Chang Ok; Kim, Yu Ri; Jang, Ji Eun; Cheong, June Won; Min, Yoo Hong; Kim, Jin Seok.

In: Oncotarget, Vol. 8, No. 50, 01.01.2017, p. 87317-87328.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Programmed cell death 1 expression is associated with inferior survival in patients with primary central nervous system lymphoma

AU - Cho, Hyunsoo

AU - Kim, Se Hoon

AU - Kim, Soo Jeong

AU - Chang, Jong Hee

AU - Yang, Woo Ick

AU - Suh, Chang Ok

AU - Kim, Yu Ri

AU - Jang, Ji Eun

AU - Cheong, June Won

AU - Min, Yoo Hong

AU - Kim, Jin Seok

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Programmed cell death 1 (PD-1) and its ligands PD-L1/PD-L2 have been shown to mediate immune evasion in various cancers, but their prognostic implications in patients with primary central nervous system lymphoma (PCNSL) are poorly understood. Therefore, we analyzed 76 PCNSL patients at initial diagnosis who were treated homogenously with high-dose methotrexate-based chemotherapy, and evaluated the prognostic roles of high immunohistochemical PD-1, PD-L1, and PD-L2 expression. The cut-off values for high PD-1 (≥ 70 cells/high power field [HPF]), PD-L1 (≥ 100 cells/HPF), and PD-L2 (≥ 100 cells/HPF) were determined by the area under the receiver operating characteristic curve. Expression of PD-1, PD-L1, and PD-L2 was high in 7.9%, 13.2%, and 42.1% patients, respectively. High PD-1, (P = 0.007) and Memorial Sloan Kettering Cancer Center (MSKCC) prognostic scoring (P = 0.019) were independently associated with inferior overall survival on multivariate analysis. High PD-1 also remained an independent prognostic factor for inferior progression-free survival (P = 0.028), as did MSKCC prognostic scoring (P = 0.041) on multivariate analysis. However, there were no differences in survival according to the expression levels of PD-L1/PD-L2 in PCNSL tumor microenvironment. Our results suggest that PD-1 may be considered a biomarker and potential therapeutic target in PCNSL.

AB - Programmed cell death 1 (PD-1) and its ligands PD-L1/PD-L2 have been shown to mediate immune evasion in various cancers, but their prognostic implications in patients with primary central nervous system lymphoma (PCNSL) are poorly understood. Therefore, we analyzed 76 PCNSL patients at initial diagnosis who were treated homogenously with high-dose methotrexate-based chemotherapy, and evaluated the prognostic roles of high immunohistochemical PD-1, PD-L1, and PD-L2 expression. The cut-off values for high PD-1 (≥ 70 cells/high power field [HPF]), PD-L1 (≥ 100 cells/HPF), and PD-L2 (≥ 100 cells/HPF) were determined by the area under the receiver operating characteristic curve. Expression of PD-1, PD-L1, and PD-L2 was high in 7.9%, 13.2%, and 42.1% patients, respectively. High PD-1, (P = 0.007) and Memorial Sloan Kettering Cancer Center (MSKCC) prognostic scoring (P = 0.019) were independently associated with inferior overall survival on multivariate analysis. High PD-1 also remained an independent prognostic factor for inferior progression-free survival (P = 0.028), as did MSKCC prognostic scoring (P = 0.041) on multivariate analysis. However, there were no differences in survival according to the expression levels of PD-L1/PD-L2 in PCNSL tumor microenvironment. Our results suggest that PD-1 may be considered a biomarker and potential therapeutic target in PCNSL.

UR - http://www.scopus.com/inward/record.url?scp=85031761419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031761419&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.20264

DO - 10.18632/oncotarget.20264

M3 - Article

AN - SCOPUS:85031761419

VL - 8

SP - 87317

EP - 87328

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 50

ER -